Previous close | 57.70 |
Open | 56.70 |
Bid | 56.80 x N/A |
Ask | 59.10 x N/A |
Day's range | 57.70 - 57.70 |
52-week range | 56.70 - 98.80 |
Volume | |
Avg. volume | 0 |
Market cap | 1.756B |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.24 |
Earnings date | 15 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 26 Nov 2009 |
1y target est | N/A |
Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy (BLC®) using a mobile capital equipment model. The initiative is aligned with a recently executed agreement between Karl Storz and ForTec Medical, aimed at providing on-demand Saphira™ BLC equipment to hospitals in the U.S. leveraging ForTec's utilization-driven mobile equipment business model.
Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b